KDventures AB said it will write off the entire remaining book value tied to potential additional purchase considerations from Organon’s 2021 acquisition of its former portfolio company Forendo, after Organon discontinued development of Forendo’s remaining preclinical PCOS drug candidate. The write-off will be reported in KDventures’ first-quarter 2026 interim report.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030449OMX_____CNEWS_EN_GNW1001167867_en) on March 03, 2026, and is solely responsible for the information contained therein.